搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

Your Good Partner in Biology Research

Human Apolipoprotein A2,apo-A2 ELISA Kit

  • 中文名稱:
    人載脂蛋白A2(apo-A2)酶聯(lián)免疫試劑盒
  • 貨號:
    CSB-E13504h
  • 規(guī)格:
    96T/48T
  • 價格:
    ¥3600/¥2500
  • 其他:

產品詳情

  • 產品描述:
    人載脂蛋白A2(apo-A2)酶聯(lián)免疫試劑盒(CSB-E13504h)為雙抗夾心法ELISA試劑盒,定量檢測血清、血漿、組織勻漿樣本中的APOA2含量。APOA2是一種載脂蛋白,位于高密度脂蛋白顆粒中,具有膽固醇轉移活性,參與動物器官再生、對雌激素和糖皮質激素的反應。其位于細胞外空間,是乳糜微粒、球形高密度脂蛋白顆粒和極低密度脂蛋白顆粒的一部分,與家族性高膽固醇血癥有關。試劑盒檢測范圍為1 ng /mL-800 ng/mL,適用于心血管疾病機制研究、代謝性疾病動物模型分析、藥物干預實驗或體外組織樣本中脂蛋白代謝相關指標的科研檢測,檢測結果可為探索 apo - A2 在脂質代謝調控、炎癥反應及疾病發(fā)生發(fā)展中的作用提供定量依據本品僅用于科研,不用于臨床診斷,產品具體參數(shù)及操作步驟詳見產品說明書。
  • 別名:
    APO A2 ELISA Kit; Apo AII ELISA Kit; Apo-AII ELISA Kit; APOA 2 ELISA Kit; ApoA II ELISA Kit; ApoA-II ELISA Kit; APOA2 ELISA Kit; APOA2_HUMAN ELISA Kit; APOAII ELISA Kit; Apolipoprotein A II ELISA Kit; Apolipoprotein A-II(1-76) ELISA Kit; Apolipoprotein A2 ELISA Kit; Apolipoprotein AII ELISA Kit; ApolipoproteinA II ELISA Kit; OTTHUMP00000032244 ELISA Kit
  • 縮寫:
  • Uniprot No.:
  • 種屬:
    Homo sapiens (Human)
  • 樣本類型:
    serum, plasma, tissue homogenates
  • 檢測范圍:
    1 ng /mL-800 ng/mL
  • 靈敏度:
    1 ng/mL
  • 反應時間:
    1-5h
  • 樣本體積:
    50-100ul
  • 檢測波長:
    450 nm
  • 研究領域:
    Immunology
  • 測定原理:
    quantitative
  • 測定方法:
    Sandwich
  • 精密度:

    Intra-assay Precision (Precision within an assay): CV%<8%

    Three samples of known concentration were tested twenty times on one plate to assess.

    Inter-assay Precision (Precision between assays): CV%<10%

    Three samples of known concentration were tested in twenty assays to assess.

  • 線性度:

    To assess the linearity of the assay, samples were spiked with high concentrations of human apo-A2 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.

     

    Sample

    Serum(n=4)

    1:1000

    Average %

    103

    Range %

    96-110

    1:2000

    Average %

    96

    Range %

    89-103

    1:4000

    Average %

    99

    Range %

    92-105

    1:8000

    Average %

    95

    Range %

    88-101

  • 回收率:

    The recovery of human apo-A2 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.

    Sample Type

    Average % Recovery

    Range

    Serum (n=5)

    104

    97-110

    EDTA plasma (n=4)

    98

    93-103

  • 標準曲線:

    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.

    ng/ml

    OD1

    OD2

    Average

    Corrected

    800

    2.570

    2.634

    2.602

    2.409

    267

    2.148

    2.067

    2.107

    1.915

    89

    1.627

    1.618

    1.623

    1.430

    30

    1.074

    1.029

    1.051

    0.859

    10

    0.522

    0.531

    0.527

    0.334

    3

    0.444

    0.453

    0.448

    0.256

    1

    0.254

    0.244

    0.249

    0.056

    0

    0.195

    0.190

    0.193

     

  • 數(shù)據處理:
  • 貨期:
    3-5 working days

產品評價

相關問答

 常見問題解答
Q:

請問該試劑盒的標準品是重組蛋白還是純化的人血漿?

A:
該試劑盒(CSB-E13504h)的標準品為293細胞衍生的重組蛋白。

靶點詳情

  • 功能:
    May stabilize HDL (high density lipoprotein) structure by its association with lipids, and affect the HDL metabolism.
  • 基因功能參考文獻:
    1. Weight loss resulted from a reduction of HDL in both APOE-II genotypes. However, in C homozygote carriers, it was shown that HDL3 reduced significantly and leads to a general shift toward larger size HDL subfractions after intervention, while in T allele carriers HDL2 decreased significantly and weight loss leads to shift toward smaller size HDL subfractions. PMID: 28545455
    2. There was a statistically significant interaction between APOA2 polymorphism and dietary fatty acids intake on oxidative stress n patients with type 2 diabetes PMID: 27271094
    3. This study detected a reduced level of heterodimer apoA2-ATQ/AT and a specific apoA2 isoform hypo-processing pattern in the sera of autoimmune pancreatitis patients. PMID: 29481802
    4. In type 2 diabetes mellitus patients, the dietary intake of antiinflammatory fatty acids, such as omega-3 PUFAs and MUFAs, could reduce the inflammatory effects associated with the Apolipoprotein A2 CC genotype. In addition, proinflammatory fatty acids, such as SFAs, could overcome the antiinflammatory effect of the T-allele. PMID: 28359369
    5. data support an SR-B1 nibbling mechanism that is similar to that of streptococcal serum opacity factor, which also selectively removes CE and releases apoAI, leaving an apoAII-rich remnant. PMID: 28373285
    6. A new missense mutation in an Iranian population has a significant association with high-density lipoprotein cholesterol levels. PMID: 26590203
    7. ApoAII-ATQ/AT not only distinguished the early stages of pancreatic cancer from healthy controls but also identified patients at high risk for pancreatic malignancy. PMID: 26549697
    8. Plasma apoB pool size of VLDL containing apoA-II is much smaller than that of VLDL without apoA-II, and this was caused by a very low rate of secretion of this VLDL type into plasma. PMID: 26071654
    9. APOA-II polymorphism and oxidative stress is associated with poor prognosis in patients with type 2 diabetes. PMID: 26104730
    10. Apolipoprotein AII was detected as a protein associated with the urinary protein/urinary creatinine levels in pediatric idiopathic steroid-sensitive nephrotic syndrome PMID: 24633472
    11. Apolipoprotein A-II/B significantly improves risk prediction of overall survival, also in carotid surgery patients with lower LDL levels PMID: 25953375
    12. Apolipoprotein A-II and the regulation of high density lipoproteins in cardiovascular disease. [Review] PMID: 24012775
    13. We have cloned the cDNA encoding human ApoA-II and achieved its high-level secreting expression with a yield of 65 mg/L of yeast culture PMID: 24116940
    14. identified a statistically significant interaction between the APOA2 -265T > C variant and higher-fat dairy food intake in the Boston Puerto Ricans and replicated this relation in the GOLDN study PMID: 24108135
    15. Clinical studies demonstrate that apoA-II is a strong predictor of risk for CVD. There is no evidence, however, that selective therapeutic modification of apoA-II impacts on atherosclerosis and clinical outcomes.[review] PMID: 21501035
    16. These data suggest Apo-AII-containing high-density lipoproteins (HDL) formed intrahepatically are likely cholesterol-rich compared to the smaller intracellular lipid-poor Apo A-I HDL. PMID: 23025327
    17. Enrichment of apo A-II in high-density lipoprotein particles has atheroprotective effects and apo A-II may become a target for the treatment of atherosclerosis. PMID: 23241412
    18. We conclude that apoA-II plays a significant role in apoE-associated risk of incident CVD in women with high levels of HDL-C and CRP. PMID: 22723940
    19. APOA2 m265 genotype may be associated with eating behaviours and dietary modulation of plasma ghrelin. PMID: 21386805
    20. a gene-diet interaction involving the APOA2 -265T>C SNP and saturated fat intake determines body weight in a Mediterranean and an Asian populations PMID: 20975728
    21. Human apolipoprotein A-II inhibits the production of interferon-gamma by concanavalin A-stimulated mouse and human CD4-positive T cells. PMID: 21300819
    22. Low apolipoprotein-A2 is associated with metastatic renal cell cancer. PMID: 20022911
    23. ApoA-II plays a crucial role in triglyceride catabolism by regulating lipoprotein lipase activity, at least in part, through HDL proteome modulation. PMID: 19910634
    24. The serum apoA-II concentrations confer risk for MetS and diabetes and exhibit evidence of anti-inflammatory properties among Turks. PMID: 19817643
    25. In metabolic syndrome, fenofibrate, but not atorvastatin, influences high density lipoprotein metabolism by increasing the transport of APOA2 particles. PMID: 19651918
    26. when expressed in transgenic mice, HDL shows antioxidant properties PMID: 11971944
    27. Overexpression in transgenic mice does not increase their susceptibility to insulin resistance and obesity PMID: 12032642
    28. Evaluated as a positional candidate gene for familial Type II diabetes, altered lipid concentrations, and insulin resistance PMID: 12136402
    29. Crystallographic studies of apo A-II and its complex with lipid surrogate beta-octyl glucoside show that disulfide-linked dimers of apo A-II form amphipathic alpha-helices which aggregate into tetramers. PMID: 12269810
    30. Carriers of a novel splice-site mutation in the LDL-receptor gene were simultaneously homozygous for the -265C variant of apoA-II thus concluding that one variant of the apoA-II gene was associated with reduced plasma LDL cholesterol in FH patients PMID: 12522687
    31. This protein inhibits high density lipoprotein remodeling and lipid-poor apolipoprotein A-I formation PMID: 12690114
    32. Genetic association of plasma apolipoprotein A-II levels with familial combined hyperlipidemia. PMID: 12738753
    33. Analysis of trancription factors that bind response elements in the apoA-II promotor and modulate transcription. PMID: 12959642
    34. apoA-II affects both the structure and the dynamic behavior of HDL particles and selectively modifies lipid metabolism PMID: 14967812
    35. In transgenic mice overexpressing the human apoA-II gene, plasma human apoA-II concentration was positively correlated with blood glucose levels. PMID: 14988251
    36. this protein-exonic splicing enhancer interaction is able to promote the incorporation of exon 3 in mRNA and suggest that they can rescue the splicing despite the noncanonical 3' splice site. PMID: 15247216
    37. Overexpressed human apoA-II in mice impairs HDL protection of apoB-lipoproteins from oxidation. Displacement of PON1 by apoA-II may explain why PON1 is found in HDL particles with apoA-I, not apoA-II, & apo-A-II-rich HDL's poor antiatherogenic properties. PMID: 15388641
    38. results indicate a significant association between the T265C APOA-II polymorphism and levels of visceral adipose tissue in premenopausal women present in white but not African-American women PMID: 15833935
    39. Characterization of regulatory elements found in the apoA-II exon 3 and its flanking introns that are involved in the control of apoA-II exon 3 splicing. PMID: 16254078
    40. the association of apoA-II with triglyceride-rich lipoproteins occurs in the circulation and induces postprandial hypertriglyceridemia PMID: 16990646
    41. ApoA-II adopts a beltlike structure in which the protein helices wrap around the lipid- bilayer reconstituted high density lipoprotein (rHDL) disc. PMID: 17264082
    42. ApoAII is efficiently reabsorbed in kidney proximal tubules in relation to its plasma concentration PMID: 17652309
    43. carriers of the minor allele for Apo A-II -265T/C (CC/TC) have a lower postprandial response compared with TT homozygotes PMID: 17709437
    44. ApoA-II is associated with a decreased risk of future coronary artery disease in apparently healthy people, implying that apoA-II itself exerts effects on specific antiatherogenic pathways. PMID: 17923573
    45. APOAII rs5082 polymorphism may have a role in reducing risk of coronary artery disease in an Australian male population PMID: 18179799
    46. results for dimeric apolipoprotein AII are similar to those we have reported for the monomeric apolipoprotein CI, which has a similar secondary structure but a different peptide sequence and net charge PMID: 18652418
    47. procoagulant activities of plasma factor VIIc and factor Xc are positively and independently associated with concentrations of the high-density lipoprotein apolipoprotein, apo A-II PMID: 18766253
    48. small sizes (i. e., number of kringle-4 repeats in the gene) of apolipoprotein (a) are risk factors for the development of atherothrombosis. (review) PMID: 19069164
    49. Results indicate that CETP inhibition increases plasma concentrations of apoA-II by delaying HDL apoA-II catabolism and significantly alters the remodeling of apoA-II-containing HDL subpopulations. PMID: 19193611
    50. The available data does not support a role for common variants in APOA2 on type 2 diabetes susceptibility or related quantitative traits in Northern Europeans PMID: 19216768

    顯示更多

    收起更多

  • 亞細胞定位:
    Secreted.
  • 蛋白家族:
    Apolipoprotein A2 family
  • 組織特異性:
    Plasma; synthesized in the liver and intestine.
  • 數(shù)據庫鏈接:

    HGNC: 601

    OMIM: 107670

    KEGG: hsa:336

    STRING: 9606.ENSP00000356969

    UniGene: Hs.237658